Novo Nordisk A/S - Share repurchase programme
Bagsværd, Denmark, 8 August 2019 – On 7 May 2019, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules"). This programme is part of the overall share repurchase programme of up to DKK 15 billion to be executed during a 12-month period beginning 1 February 2019.
Under the programme initiated 7 May 2019, Novo Nordisk has repurchased B shares for an amount up to DKK 2.7 billion in the period from 8 May 2019 to 7 August 2019. The programme is now concluded.
Since the announcement as of 5 August 2019, the following transactions have been made under the programme:
|Accumulated, last announcement||7,795,400||2,560,398,451|
|5 August 2019||142,000||324.84||46,126,809|
|6 August 2019||116,080||323.32||37,531,075|
|7 August 2019||171,028||327.10||55,943,518|
|Accumulated under the programme||8,224,508||2,699,999,853|
The details for each transaction made under the share repurchase programme are published on novonordisk.com.
With the transactions stated above, Novo Nordisk owns a total of 30,568,156 B shares of DKK 0.20, corresponding to 1.3% of the share capital, as treasury shares. The total amount of A and B shares in the company is 2,400,000,000 including treasury shares.
Novo Nordisk expects to repurchase B shares for an amount up to DKK 15 billion during a 12-month period beginning 1 February 2019. As of 7 August 2019, Novo Nordisk has since 1 February 2019 repurchased a total of 23,401,012 B shares at an average share price of DKK 326.27 per B share equal to a transaction value of DKK 7,634,953,454.
|Anne Margrethe Hauge||+45 4442 email@example.com|
|Ken Inchausti (US)||+1 609 240 firstname.lastname@example.org|
|Peter Hugreffe Ankersen||+45 3075 email@example.com|
|Valdemar Borum Svarrer||+45 3079 firstname.lastname@example.org|
|Ann Søndermølle Rendbæk||+45 3075 email@example.com|
|Kristoffer Due Berg (US)||+1 609 235 firstname.lastname@example.org|
Upcoming Life Sciences Events
- August 2020
- ChinaBio® Partnering Forum 2020 Digital
- Biotechgate Digital Partnering Event
- September 2020
- Basel: Pharma-Biotech Product & Company Valuation